To assess efficacy of intravitreal ranibizumab in retinal pigment epithelium tears secondary to neovascular age-related macular degeneration.
The Ranibizumab In Pigment epithelial tears secondary to age-related macular degeneration (RIP) study is a prospective, single-arm, multicenter, investigator-initiated trial. Twenty four eyes of 24 patients with a retinal pigment epithelium tear secondary to age-related macular degeneration received monthly intravitreal injection of 0.5mg ranibizumab for 12 months, together with monthly assessments of morphologic and functional efficacy parameters. Primary outcome measure was mean best-corrected visual acuity at final visit compared with baseline.
Mean best-corrected visual acuity remained stable over the 12-month study period with 50.3 Early Treatment of Diabetic Retinopathy Study letters (±18.7; Snellen equivalent 20/100) at baseline and 52.9 letters (±19.7; Snellen equivalent 20/100) at final visit (P = 0.39). One eye (4%) experienced a vision loss of ≥15 letters, and 2 eyes (8%) gained ≥15 letters. Mean central retinal thickness decreased from 571 µm (±185 µm) to 436 µm (±171 µm; P = 0.0001). Vision-related quality of life was stable with a mean VFQ-25 score of 79.0 (±10.8) at baseline and 74.3 (±13.9) at final visit (P = 0.12).
In retinal pigment epithelium tears secondary to age-related macular degeneration, monthly intravitreal ranibizumab therapy results in stabilization of visual acuity over 12 months.
The results of this prospective multicenter study emphasize the role of frequent anti–vascular endothelial growth factor therapy for the stabilization of visual acuity after the occurrence of a pigment epithelial tear secondary to age-related macular degeneration.
*Department of Ophthalmology, University of Bonn, Bonn, Germany;
†Department of Ophthalmology, University of Münster, Münster, Germany;
‡Department of Ophthalmology, Ludwig Maximilian University, Munich, Germany; and
§Department of Ophthalmology, St. Franziskus Hospital, Münster, Germany.
Reprint requests: Tim U. Krohne, MD, FEBO, Department of Ophthalmology, University of Bonn, Ernst-Abbe-Straße 2, Bonn D-53127, Germany; e-mail: email@example.com
P. P. Larsen, Novartis: F; A. Oishi, Alcon: F; Bayer: R; Novartis: R; P. K. R. Heymer, Novartis: F; C. R. Clemens, Novartis: F; S. König, Novartis: F; M. Gutfleisch, Alcon: F; Novartis: F; Ophthotech: F; Pfizer: F; Roche: F; D. Pauleikhoff, Alcon: F; Allergan: F; Acucela: F; Bayer: F; Genetech: F; Novartis: F; Ophthotech: F; Pfizer: F; Roche: F; N. Eter, Novartis: F; A. Wolf, Bayer: F; DORC: R; GenSight: F; Novartis: C, F, R; Oertli: R; Ophthotech: F; Optos: C, R; Roche: F; F. G. Holz, Acucela: C, F; Allergan: F, R; Bayer: C, F, R; Bioeq: C, F; Boehringer-Ingelheim: C; Carl Zeiss MediTec: F, R; Genentech: C, F, R; Heidelberg Engineering: C, F, R; Merz: C, F; NightstarX: F; Novartis: C, F, R; Optos: F; Pixium: F; Roche: C, F; Thea: C; T. U. Krohne, Alimera Sciences: C, R; Bayer: C, F, R; Heidelberg Engineering: R; Novartis: C, F, R. The remaining author have no financial/conflicting interests to disclose.